N/A N=188 Health Gatherings - For Your Health After Cancer
Prostate Neoplasm · Genital Neoplasms, Male · Urogenital Neoplasms
Primary: Change in Symptom Burden as Measure by EPIC-S. — 30.1; 32.1; 34.7; 35.8 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Study of the TearCare System in Dry Eye Disease
Dry Eye
Primary: Mean Change in Tear Break-Up Time (TBUT) at 1-month From Baseline — 3.1 seconds
N/A N=80 Low Nicotine Cigarettes Plus Electronic Cigarettes
Tobacco Dependence
Primary: Urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) — 505.6; 459.1; 373.3; 180.5 pg/mg creatinine — p=0.017
Phase 1 N=53 A Study of LY3451838 in Healthy Participants
Healthy
Primary: Number of Participants With Any Treatment Emergent Adverse Event — 4; 5; 4; 6 Participants
Phase 4 N=83 Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Mild Cognitive Impairment
Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048
N/A N=181 Study Of Drinks With Artificial Sweeteners in People With Type 2 Diabetes
Type 2 Diabetes
Primary: HbA1c — 7.19; 7.20; 7.13; 7.43 Hba1c(%)
Phase 1 N=16 A Safety Study of LY3526318 in Healthy Participants
Healthy
Primary: Part A - SAD, Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time 0 to Infinity (AUC 0-∞) of LY3526318 — 147978; 131271; 137814; 76902…
N/A N=5 A Study of Azilsartan in Children From 6 to Less Than 16 Years Old With High Blood Pressure
Hypertension
Primary: Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) — 0 Participants
Phase 1 N=14 A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)
End-Stage Renal Disease · End-Stage Kidney Disease · Kidney Failure, Chronic
Primary: Part 1: Number of Participants Who Experience One or More Bleeding Related Adverse Events (AE) — 0; 0 Participants
Phase 2 N=38 Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma
Primary: Number of Participants Alive With and Without Disease Progression — 4; 6; 28 Participants
N/A N=100 No Post Intubation Laryngeal Symptoms
Sore-throat · Dysphonia · Dysphagia
Primary: Sore Throat on a Scale From 0 (no Sore Throat) to 10 (Worst Possible Sore Throat) — 1.85; 1.9; 1.1; 1.62 score on a scale — p=0.03
N/A N=71 Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome
Heart Failure
Primary: Carotid-femoral Pulse Wave Velocity — -0.3; 0.4 m/s — p=0.28
Phase 4 N=5 Testing C-Raven, a Virtual Tobacco Cessation Intervention, in the Community
Tobacco Dependence
Primary: Acceptability and Feasibility as Assessed by the Number of Participants Who Complete Intervention and Surveys — 5; 5 Participants
Phase 4 N=399 Evaluation of (Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate) (Delstrigo®) as a New Strategy for Non-occupational Post Exposure Prophylaxis, a Prospective Open Label Study
Hiv
Primary: Proportion of Participants Who Did Not Complete the 28-day PEP Regimen — 114 Participants
Phase 3 N=581 Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients
Anemia
Primary: Percentage of Patients Who Have Received at Least One Study Transfusion With a Diagnosis of Renal Impairment Defined as: — 46; 45 Participants